Literature DB >> 29992648

Authors' reply to: Anti-Müllerian hormone and breast cancer risk: is the correlation possibly associated with PCOS.

Tess V Clendenen1, Joanne Dorgan2, Anne Zeleniuch-Jacquotte1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29992648      PMCID： PMC6263028          DOI： 10.1002/ijc.31728

Source DB:  PubMed          Journal:  Int J Cancer        ISSN： 0020-7136            Impact factor:   7.396


× No keyword cloud information.
  10 in total

1.  Circulating anti-Müllerian hormone and breast cancer risk: A study in ten prospective cohorts.

Authors:  Wenzhen Ge; Tess V Clendenen; Yelena Afanasyeva; Karen L Koenig; Claudia Agnoli; Louise A Brinton; Joanne F Dorgan; A Heather Eliassen; Roni T Falk; Göran Hallmans; Susan E Hankinson; Judith Hoffman-Bolton; Timothy J Key; Vittorio Krogh; Hazel B Nichols; Dale P Sandler; Minouk J Schoemaker; Patrick M Sluss; Malin Sund; Anthony J Swerdlow; Kala Visvanathan; Mengling Liu; Anne Zeleniuch-Jacquotte
Journal:  Int J Cancer       Date:  2018-02-08       Impact factor: 7.396

2.  Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome.

Authors:  P Pigny; S Jonard; Y Robert; D Dewailly
Journal:  J Clin Endocrinol Metab       Date:  2005-12-20       Impact factor: 5.958

Review 3.  Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome.

Authors:  Daniel A Dumesic; Sharon E Oberfield; Elisabet Stener-Victorin; John C Marshall; Joop S Laven; Richard S Legro
Journal:  Endocr Rev       Date:  2015-10       Impact factor: 19.871

4.  A nationwide population-based retrospective cohort study of the risk of uterine, ovarian and breast cancer in women with polycystic ovary syndrome.

Authors:  Cheng-Che Shen; Albert C Yang; Jeng-Hsiu Hung; Li-Yu Hu; Shih-Jen Tsai
Journal:  Oncologist       Date:  2014-11-19

5.  Relationship between serum müllerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women.

Authors:  Christine L Cook; Yong Siow; Amy G Brenner; Mary E Fallat
Journal:  Fertil Steril       Date:  2002-01       Impact factor: 7.329

Review 6.  The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis.

Authors:  Gurkan Bozdag; Sezcan Mumusoglu; Dila Zengin; Erdem Karabulut; Bulent Okan Yildiz
Journal:  Hum Reprod       Date:  2016-09-22       Impact factor: 6.918

7.  Polycystic ovarian syndrome (PCOS), related symptoms/sequelae, and breast cancer risk in a population-based case-control study.

Authors:  Jayeon Kim; Jennifer E Mersereau; Nikhil Khankari; Patrick T Bradshaw; Lauren E McCullough; Rebecca Cleveland; Sumitra Shantakumar; Susan L Teitelbuam; Alfred I Neugut; Ruby T Senie; Marilie D Gammon
Journal:  Cancer Causes Control       Date:  2016-01-21       Impact factor: 2.506

Review 8.  Polycystic ovary syndrome: current status and future perspective.

Authors:  Erin K Barthelmess; Rajesh K Naz
Journal:  Front Biosci (Elite Ed)       Date:  2014-01-01

9.  Diagnosis and management of polycystic ovary syndrome in the UK (2004-2014): a retrospective cohort study.

Authors:  Tao Ding; Gianluca Baio; Paul J Hardiman; Irene Petersen; Cormac Sammon
Journal:  BMJ Open       Date:  2016-07-11       Impact factor: 2.692

Review 10.  Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: a systematic review.

Authors:  Holly R Harris; Kathryn L Terry
Journal:  Fertil Res Pract       Date:  2016-12-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.